Bruker (BRKR): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
7 concentrated managers hold it (+4 vs last quarter) with a median weight of 1.5%.
Who owns Bruker?
Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the common shares: FMR (13G/A filed Aug 6, 2026) and Orbis Investment Management (13G/A filed May 15, 2026). Laukien Frank H is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders of the common shares reported on Form 13F were FMR (13.3% of the common shares), Orbis Allan Gray (11.8%) and BlackRock (7.5%).
Which institutions hold the most Bruker shares?
Per Form 13F filings as of Jun 30, 2026, as a share of the common shares (without its other class):
- 1. FMR: 13.3%
- 2. Orbis Allan Gray: 11.8%
- 3. BlackRock: 7.5%
- 4. Pallas Capital Advisors: 6.2%
- 5. Vanguard Portfolio Management: 3.2%
- 6. Vanguard Capital Management: 3.2%
- 7. Sculptor Capital: 3.0%
- 8. State Street: 2.6%
- 9. Franklin Resources: 2.1%
- 10. Sachem Head Capital Management: 1.9%
How much of Bruker do institutions own?
The 416 institutions that file 13F reported 92.9% of the common shares as of Jun 30, 2026.
Sources:13G/A by FMR (Aug 6, 2026) ↗13G/A by Orbis Investment Management (May 15, 2026) ↗All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the common shares outstanding on the cover of the company's latest report before the quarter end (May 1, 2026). Entities of the same group file separately and are not added up. With more than one share class, a 13D or 13G counts shares convertible from another class as owned, so we do not show its percentage. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Bruker revenue
Bruker reported annual revenue of $3.44 billion for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).
Well-known investors holding it
Quarter flow (concentrated managers)
Change in managers (3 → 7): 4 opened · 0 exited = +4
Net flow in the quarter: +$222M (+3.7 M shares) · bought $231M and sold $8.5MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
The set of concentrated managers changed between quarters: with the set as it was then, 5 held it last quarter (the chart point); with today's set, 3 (the base for the change).
Concentrated managers holding it
- Sachem Head Capital ManagementNew$175M3.6%+3.6 pp
- Think InvestmentsIncreased$38.8M4.8%+0.7 pp
- Forest Avenue Capital ManagementNew$25.4M1.1%+1.1 pp
- Glenview Capital ManagementNew$15.2M0.3%+0.3 pp
- Gamma As SectorReduced$9.2M2.0%−1.3 pp
- Integral Health Asset ManagementNew$9.0M0.4%+0.4 pp
- Lawson Kroeker Investment ManagementReduced$5.6M1.5%−0.7 pp
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of BRKR (all 13F filers)
- FMR20.2 MInvestment firm · 13.29% of the company+4.1 M
- Orbis Allan Gray17.9 MInvestment firm · 11.79% of the company0
- BlackRock11.4 MIndex manager · 7.49% of the company+227 K
- Pallas Capital Advisors9.5 MType not verified · 6.23% of the company+2,157
- Vanguard Portfolio Management4.9 MIndex manager · 3.21% of the company+32 K
- Vanguard Capital Management4.9 MIndex manager · 3.19% of the company+42 K
- Sculptor Capital4.6 MType not verified · 3.04% of the company+1.4 M
- State Street4.0 MIndex manager · 2.64% of the company+109 K
- Franklin Resources3.2 MInvestment firm · 2.12% of the company+310 K
- Sachem Head Capital Managementconcentrated2.9 MInvestment firm · 1.91% of the company+2.9 M
- Shares
- 20.2 M
- Change
- +4.1 M
- % of the company
- 13.29%
See more
- Type
- Investment firm
- Value
- $1.2 bn
- Shares
- 17.9 M
- Change
- 0
- % of the company
- 11.79%
See more
- Type
- Investment firm
- Value
- $1.1 bn
- Shares
- 11.4 M
- Change
- +227 K
- % of the company
- 7.49%
See more
- Type
- Index manager
- Value
- $686M
- Shares
- 9.5 M
- Change
- +2,157
- % of the company
- 6.23%
See more
- Type
- Type not verified
- Value
- $571M
- Shares
- 4.9 M
- Change
- +32 K
- % of the company
- 3.21%
See more
- Type
- Index manager
- Value
- $294M
- Shares
- 4.9 M
- Change
- +42 K
- % of the company
- 3.19%
See more
- Type
- Index manager
- Value
- $292M
- Shares
- 4.6 M
- Change
- +1.4 M
- % of the company
- 3.04%
See more
- Type
- Type not verified
- Value
- $278M
- Shares
- 4.0 M
- Change
- +109 K
- % of the company
- 2.64%
See more
- Type
- Index manager
- Value
- $242M
- Shares
- 3.2 M
- Change
- +310 K
- % of the company
- 2.12%
See more
- Type
- Investment firm
- Value
- $194M
- Sachem Head Capital Managementconcentrated
- Shares
- 2.9 M
- Change
- +2.9 M
- % of the company
- 1.91%
See more
- Type
- Investment firm
- Value
- $175M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- -0.9%
- Net margin
- -2.0%
- ROE
- -3.0%
- Revenue (TTM)
- $3.5 bn
- Revenue growth
- 1.6%
- Net income (TTM)
- $-71.2M
- Net debt / EBITDA
- 8.2x
- Free cash flow (TTM)
- $93.9M
- Quality vs sector
- 27/100
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 151.8 M
There is a jump that may be an undetected split: we do not show the changes.
- Buybacks (FY 2025)
- $10.0M
- Share issuance
- $7.9M
- Stock-based compensation
- $20.2M0.6% of revenue
- Dividends paid
- $22.8M
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Interest coverage (operating income ÷ interest)
- 1.1 timesfiscal 2025
- Debt due within 12 months
- $10.1M0.05 times cash and investments
- Year 1$11.9M
- Year 2$19.3M
- Year 3$20.4M
- Year 4$539M
- Year 5$10.9M
- Later$1.3 bn
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
«Mr. Bernard currently serves as Chief Executive Officer of QIAGEN N.V. He joined QIAGEN in 2015 to lead its growing molecular diagnostics business and was…»
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
«Bruker announces the addition of Diagnostics Industry leader Jack Phillips to its Board of Directors as of January 2026»
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Kodiak SciencesKOD · 7 managers
- Rapport TherapeuticsRAPP · 7 managers
- Research Alliance Corporation IIIRACC · 7 managers
- Achieve Life SciencesACHV · 6 managers
- Artiva BiotherapeuticsARTV · 6 managers
- GeneDx HoldingsWGS · 8 managers